<DOC>
	<DOCNO>NCT00306553</DOCNO>
	<brief_summary>The purpose study evaluate specific cellular immune response melanoma patient vaccinate Melan-A VLP vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Melan-A VLP Vaccine Advanced Stage Melanoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Able provide write informed consent . Able willing complete protocol requirement . Age : 18 year old . Histological confirm stage III IV melanoma . At least one confirm detectable target lesion HLAA*0201 haplotype Expected survival least 6 month . Full recovery surgery . Able undergo either CT scan MRI scan tumor assessment . Washout period 4 week chemotherapy All AEs form prior anticancer therapy resolve ≤ Grade 1 . Sexually active male use adequate contraception throughout study period 3 month thereafter . Females child bear potential use adequate contraception throughout study period 3 month thereafter , oral contraception doublebarrier local contraception ( intrauterine device plus condom spermicidal gel plus condom ) , negative serum pregnancy test within 4 week prior first dose vaccine . Pregnant nursing . Use investigational drug within 30 day enrolment . Known suspected brain metastasis . Current use immunosuppressive drug concomitant medication could potentially interfere study drug Presence significant cardiovascular , renal , pulmonary , endocrine , infectious , neurological bone marrow function disorder Serum test positive HIV , HBV , HCV . Active autoimmune disease severe allergy . Current diagnosis history relevant severe psychiatric disorder compromise patient ’ ability understand patient information , give informed consent , comply trial protocol complete study . Abuse alcohol recreational drug . Previous vaccination MelanA analog peptide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
</DOC>